Frequently Asked Questions

Samples – Requirements, Logistics and Compatibility

Human Sample Volume Requirements
MAP Volume Required
Serum or plasma Other fluids*
Human DiscoveryMAP® 1 mL 3 mL
Human ExplorerMAP™ 400 µL 800 µL
Human OncologyMAP® 500 µL 2 mL
HumanMAP® 120 µL 650 µL
Human CardiovascularMAP® 350 µL 700 µL
Human AngiogenesisMAP® 200 µL 500 µL
Human InflammationMAP® 100 µL 200 µL
Human ImmunoMAP® 120 µL 650 µL
Human NeuroMAP™ 150 µL 300 µL
Human MetabolicMAP® 100 µL 350 µL
Human KidneyMAP® 100 µL 350 µL
Human TruCulture® MAP 100 µL 200 µL (TruCulture® Supernatant)
Human CytokineMAP® A 50 µL 100 µL
Human CytokineMAP® B 50 µL 100 µL
Vectra® DA** 300 µL n/a
* Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
** Serum is the only accepted sample type for Vectra DA testing. If MAP and Vectra DA testing services are requested, please provide a separate electronic sample manifest and sample aliquot for Vectra DA testing. All Vectra DA testing is performed at Crescendo Biosciences, Inc.
Simoa™ Services
Biomarker LLOQ*
(Serum and Plasma)
(Undiluted Samples)
Volume Required
Serum or plasma Other fluids**
B Lymphocyte Chemoattractant (BLC, CXCL-13) 0.64 pg/mL 0.064 pg/mL 50 µL 150 µL
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) 0.036 pg/mL 0.009 pg/mL 100 µL 150 µL
Interferon gamma (IFN-gamma) 0.019 pg/mL 0.0095 pg/mL 150 µL 150 µL
Interleukin-1 beta (IL-1 beta) 0.0313 pg/mL 0.016 pg/mL 150 µL 150 µL
Interleukin-2 (IL-2) 0.050 pg/mL 0.025 pg/mL 150 µL 150 µL
Interleukin-5 (IL-5) 0.052 pg/mL 0.026 pg/mL 150 µL 150 µL
Interleukin-6 (IL-6) 0.091 pg/mL 0.0046 pg/mL 50 µL 150 µL
Interleukin-10 (IL-10) 0.0368 pg/mL 0.0092 pg/mL 100 µL 150 µL
Interleukin-12 Subunit p40 (IL-12p40) 7.300 pg/mL 0.730 pg/mL 50 µL 150 µL
Interleukin-17A (IL-17A) 0.048 pg/mL 0.012 pg/mL 100 µL 150 µL
Tumor Necrosis Factor-alpha (TNF-α) 0.078 pg/mL 0.020 pg/mL 100 µL 150 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

If your volumes are not sufficient, please contact Myriad RBM for other options and information.
Serum, plasma, urine, cell culture supernatants, CSF, and BALF are our standard acceptable sample types. All other sample types will be handled as a custom service and some may not be feasible for testing.
Once samples have been released for testing by Myriad RBM, most samples are completed within 10 business days. Longer times are required if a minimum number of samples is not submitted for certain MAPs.
If the volume of the sample is less than the required amount (please see sample volume requirements), there may not be enough sample to test all analytes. The subsequent report may contain (quantity not sufficient) results.
Our MAP services require at least 50 samples be sent in one batch for testing. Smaller numbers of samples can be submitted but the normal two week turnaround is no longer valid. The samples will be tested when at least 50 are scheduled.

Samples should be shipped to Myriad RBM on dry ice via overnight courier to:

Kalyn Sowell
Myriad RBM, Inc
3300 Duval Road
Austin, TX 78759
Phone: (512) 835-8026
Samples may be sent in a variety of tubes including screw and snap top microcentrifuge tubes. Microtiter plates are also acceptable. Please ensure that tubes and plates are packaged and sent in such a way that evaporation or leakage does not occur during shipping.
Yes. Please indicate that you would like samples returned to you on the sample submission form. Please include the carrier you would like us to use and the account number to which this may be billed.
No, but we have recommendations that we can provide upon request. Please e-mail to receive more information about our recommended storage facilities.
Tissue samples should be collected, weighed, and added to lysis buffer (100 mg of tissue per 900 µL lysis buffer. Our recommended lysis buffer is 50mM Tris-HCL with 2mM EDTA, pH 7.4. If the samples are not homogenized immediately then the samples should be frozen in liquid nitrogen and stored at -80° C. While EDTA is a good inhibitor of divalent metal requiring proteases, you may want to minimize other protease activity by adding the following inhibitors: aprotinin, antipain, leupeptin, and pepstatin A (all at 1ug/ml) and 2mM PMSF (phenylmethylsulfonyl flouride). Tissues may be homogenized using a Potter-Elvehjem homogenizer (Teflon pestle and glass mortar) attached to a variable-speed drill, a polytron or a tissuemizer. During the homogenization process, the tube should be submersed in an ice bath to maintain the sample at 2-8° C. Following homogenization, the tissue preparation is centrifuged for 2 minutes in a microfuge at 13,000xg. Making sure that the cell pellet is not disturbed, aspirate the supernatant.
Back to Top

MAPs and Testing Capabilities

Replicates are not necessary as our assays use automated liquid handling and are validated to have minimal lot to lot and run to run variability.
Myriad RBM supports GLP studies. If you would like your study conducted according to GLP guidelines, please be sure to request this from your sales representative as an additional cost is associated.
Yes, in fact, our assays are validated to clinical laboratory standards. We have been CLIA accredited since 2006.
Yes, typically we can upload biomarker data directly to their data management systems, but a consultation is necessary to confirm compatibility. Please contact your local sales representatives for more information.
Myriad RBM’s multi-analyte profiles (MAPs) have been validated to Clinical Laboratory Standards Institute (formerly NCCLS) guidelines. These are based upon the principles of immunoassay and rigorously examine the fundamental assay parameters of least detectable dose, lower limit of quantification, precision, cross-reactivity, linearity, spike-recovery, dynamic range, matrix interference, freeze-thaw stability, and short-term sample stability.
Contact your local sales representative to discuss custom analyte testing, reporting, and development. Validated ELISA assays can be performed to complete a testing menu.
Yes, custom analyte selections are available. Please contact your sales representative for pricing and volume requirements.
Many assays found in the human products have been tested using primate samples, showing that many of the human assays can detect the corresponding monkey analyte.
There will most likely be discrepancies in absolute values seen between results from different platforms. For most assays, we use the recommended matched antibody pair and standard from a reliable source. Currently, no “gold standard” exists for comparing assay platforms.
Back to Top


Click here to download an example of Myriad RBM’s standard biomarker data report.

Data is transmitted via secure email to the recipient(s) listed on the Sample Submission Form. The standard report format is an Excel® spreadsheet and can be viewed by clicking the link within the secure message and opening the Sample Report attachment. We can also upload data to data management sites and provide some custom reporting upon request. Please contact your sales representatives or for more details regarding custom reporting capabilities and pricing.
Unless otherwise specified by the client, Myriad RBM’s receiving personnel will use the simplest unique identifier printed on the sample’s label. For instance, if a barcode is present on the sample’s label, then the barcode will be used as the sample identifier in the standard data report. If a specific identifier or format is required, please contact our Client Services team at
Myriad RBM’s standard data reports are delivered as excel files via secure e-mail. If an alternate method of delivery is required, please contact our Client Services team at
The LLOQ (Lower Limit of Quantitation) is the lowest concentration of an analyte in a sample that can be reliably detected and at which the total error meets the laboratory’s requirements for accuracy. In our case, the laboratory’s requirement for accuracy is the concentration of an analyte at which the coefficient of variation of replicate standard samples is 30%.
The LDD (Least Detectable Dose) is the concentration interpolated by the mean plus 3 standard deviations of 20 standard diluent blank readings.
NR stands for Not Reported. All reports including NR values will contain comment boxes explaining why measurements for an analyte have not been reported.
QNS means Quantity Not Sufficient for analysis. QNS is routinely used when there is not ample sample volume for testing.
Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is defined as the concentration at which the CV is 30%.

Regulatory agencies do not currently provide guidelines for data analysis regarding which specific numbers should be assigned to values that are < LLOQ. The following are methods that have been used in practice.

  1. If the data all come from a single lot of reagents, we can assign some percentage of LLOQ to values, such as 50% of LLOQ. FDA reviewers consider that 0 is not a good choice here, since we are not sure that there is absolutely no analyte in the sample.
  2. LLOQs may vary between reagent lots causing a potential problem to arise if results data come from multiple lots. If a group of treated patient samples are run with one lot, and a group of comparator control samples are run with a different lot, apparent separation between the two groups may be artificially increased if the LLOQ for the treated group is higher than the LLOQ for the control group. It is desirable to use a single derived LLOQ across multiple lots, for example, by taking the average of LLOQs or the weighted average of LLOQs based on numbers of samples.
Yes. Please contact your sales representative for a price quote.
For all measurements less than 100, we will report two significant digits. If the result is greater than or equal to 100, we will report three significant digits.
The ranges shown at the top of Myriad RBM’s standard data reports are available for serum, EDTA-plasma, and urine sample types only, when applicable. We do not report or provide ranges for any other types of samples. The Myriad RBM range is determined based on the testing of approximately 100 apparently healthy individuals and no assumption is made about the samples having a normal distribution. The range comprises the middle 95%, with the highest and lowest 2.5% of the samples excluded for each given assay.
Click here for a summary of the changes made to Myriad RBM’s biomarker data reports in August of 2012.

Yes, if demographic data has been included as unique fields either on the Excel lab report or in a custom data file, then demographic data reconciliation can be performed. Myriad RBM aims to complete reconciliation requests within 3 business days, however large volume requests may take more time.

Reconciliation requests must be formally documented, preferably in an Excel spreadsheet containing a cumulative list of all requests for a project. The request should include the following pieces of information: person making the request, request date, sample identification as applicable (barcode, subject, visit, time point), value to change, old value, new value, reason for change. Myriad RBM will note the date each change was made to our database and will return the document when each reconciliation cycle is completed.

Yes. This document (pdf) describes the available formatting options. Please contact your sales representative for a price quote.
Back to Top

Secure Email Data Transfers
All standard data reports will be sent securely beginning in April 2016.

Incoming secure messages will be delivered as a standard email from our reporting group with a subject line containing your order number “Order # 123456”.
The email will contain a link to your secure message, “Click here to view your secure message from Myriad RBM, Inc.” Upon clicking the link, your message and attachment(s) will be displayed.
Once your message is displayed, attachments are opened by clicking the attachment name. If the program is known, the attachment is opened automatically; unknown programs open in a new browser window. You may also be presented with a pop up box giving you the option to open or save the attachment to your own network drive.
When viewing the secure message, you will see a ‘Reply’ button that you can use to respond to the email.
Messages will expire 30 days after receipt.
The data will need to be resent. Contact our Client Services team at to request a resend of the data.
Data is sent securely to help protect sensitive information contained within the report.
Attachments are transmitted using 256-bit SSL encryption.
Back to Top


Kits are not provided for any sample collection except TruCulture®.
Phlebotomy supplies are not included for samples to be tested except when the TruCulture® system has been ordered. Transportation, coordination and associated costs are the responsibility of the customer.
Other stimulants are available, but require a custom manufacturing lot and a commitment to purchase a minimum number of tubes.
Ready to Order Stimulants Major Target Cells
Lipopolysaccharide (LPS) Monocytes, T-cells
Made to Order Stimulants Major Target Cells
Staphylococcal Enterotoxin type B (SE-B) Th1>>Th2
LPS + SE-B Monocytes, T-cells and Th1>>Th2
Anti-CD-3 antibody Th1>Th2
(~ 1 out of 6 donors does not respond to this type of stimulus in whole-blood)
Anti-CD3 antibody + Anti-CD28 antibody Th1, Th2, regulatory T cells
(~ 1 out of 6 donors does not respond to this type of stimulus in whole-blood)
SE-B + Anti-CD28 antibody Th1>Th2
Zymosan Granulocytes, monocytes